23^rd April 2007, London ApaTech is pleased to announce two senior management appointments to further strengthen its executive team.

John von Benecke has joined ApaTech in the position of Group Financial Controller and has responsibility for the day to day financial operations of the business, including oversight of the US subsidiary ApaTech Inc., treasury functions, order fulfillment and supply chain planning, IT and the Quality Management System.  John reports to Simon Cartmell, Chief Executive Officer.

John joins from Biocompatibles Plc where he was responsible for Business Planning and Analysis. Prior to this role John was at Abbott Laboratories where he was Commercial Controller for their Pharmaceutical and Nutritional businesses in the UK.

The second appointment is Ian Ellis, who becomes Vice President – Marketing.  Ian will be responsible for generating strategic and tactical marketing plans for existing and new products, product promotion strategies, publication plans and core promotional materials on a group-wide basis.

Ian joins from Stata-G, a consultancy firm offering marketing support to start-up and young biotech, pharmaceutical and medical device companies. Prior to this he was Sales and Marketing Director at GW Pharmaceuticals and Community Marketing Director at Elan Corporation (UK).  Ian was previously responsible for Losec, the world’s largest prescription pharmaceutical while at AstraZeneca in the mid 1990s.

Ian will also report to Simon Cartmell, Chief Executive Officer.

Commenting on these appointments CEO Simon Cartmell said these appointments further strengthen our management team and reflect the aspirations we have for the growth of ApaTech. Both John and Ian bring considerable experience and best practice from world leading organisations and from rapid growth entrepreneurial environments.  We look forward to the positive impact they will make on our business and to other appointments as we grow in the year ahead.

Contact:

Simon Cartmell, Chief Executive Officer +44 (0)208 731 4640 or +4 (0)796 645 3133

About ApaTech

ApaTech Limited, based in London, England, is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from London and Cambridge Universities, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse™ globally. The company believes that Actifuse is the first of a new class of synthetic bone graft material that combines osteo-conductive and osteo-stimulatory activities.

To date the Company has raised £11.5m of equity from 3i plc and MTI and £3m of debt from Noble Ventures.  ApaTech commercializes its products, Actifuse and ApaPore™ in 18 countries and continues to achieve rapid worldwide sales growth.